| Primary |
| Epilepsy |
48.5% |
| Drug Use For Unknown Indication |
15.9% |
| Product Used For Unknown Indication |
9.2% |
| Lennox-gastaut Syndrome |
3.9% |
| Post-traumatic Epilepsy |
3.3% |
| Grand Mal Convulsion |
2.8% |
| Complex Partial Seizures |
2.6% |
| Hodgkin's Disease Nodular Sclerosis Stage Unspecified |
2.0% |
| Migraine |
1.7% |
| Convulsion |
1.5% |
| Frontal Lobe Epilepsy |
1.3% |
| Myoclonic Epilepsy |
1.3% |
| Brain Contusion |
0.9% |
| Dysuria |
0.9% |
| Hypertension |
0.9% |
| Temporal Lobe Epilepsy |
0.9% |
| Encephalitis |
0.7% |
| Juvenile Myoclonic Epilepsy |
0.7% |
| Partial Seizures |
0.7% |
| Back Pain |
0.4% |
|
| Status Epilepticus |
20.2% |
| Hallucination, Visual |
10.7% |
| Weight Decreased |
9.5% |
| Pneumonia Aspiration |
6.0% |
| Catatonia |
4.8% |
| Urinary Tract Infection |
4.8% |
| White Blood Cell Count Increased |
4.8% |
| Calculus Urinary |
3.6% |
| Epilepsy |
3.6% |
| Hyperammonaemia |
3.6% |
| Mental Impairment |
3.6% |
| Psychotic Disorder |
3.6% |
| Urine Output Decreased |
3.6% |
| Weight Increased |
3.6% |
| Amyotrophic Lateral Sclerosis |
2.4% |
| Cholelithiasis |
2.4% |
| Drug Interaction |
2.4% |
| Drug Toxicity |
2.4% |
| Headache |
2.4% |
| Intestinal Perforation |
2.4% |
|
| Secondary |
| Epilepsy |
54.5% |
| Drug Use For Unknown Indication |
11.1% |
| Product Used For Unknown Indication |
8.3% |
| Complex Partial Seizures |
6.6% |
| Grand Mal Convulsion |
4.6% |
| Myoclonic Epilepsy |
3.2% |
| Post-traumatic Epilepsy |
3.1% |
| Convulsion |
1.6% |
| Hodgkin's Disease Nodular Sclerosis Stage Unspecified |
1.2% |
| Lennox-gastaut Syndrome |
1.2% |
| Foetal Exposure During Pregnancy |
1.0% |
| Parkinsonism |
0.9% |
| Temporal Lobe Epilepsy |
0.8% |
| Partial Seizures |
0.3% |
| Simple Partial Seizures |
0.3% |
| Constipation |
0.3% |
| Frontal Lobe Epilepsy |
0.3% |
| Schizophrenia |
0.3% |
| Influenza |
0.2% |
| Brain Oedema |
0.1% |
|
| Status Epilepticus |
17.2% |
| Epilepsy |
12.8% |
| Weight Decreased |
11.6% |
| Hallucination, Visual |
9.2% |
| Intestinal Perforation |
6.4% |
| Paralysis |
6.4% |
| Calculus Urinary |
5.6% |
| Psychotic Disorder |
3.6% |
| Speech Disorder |
3.6% |
| White Blood Cell Count Increased |
3.6% |
| Urinary Tract Infection |
3.2% |
| Weight Increased |
2.4% |
| Cholelithiasis |
2.0% |
| Hyperammonaemia |
2.0% |
| Nephrolithiasis |
2.0% |
| Protein Urine Present |
2.0% |
| Amyotrophic Lateral Sclerosis |
1.6% |
| Drug Toxicity |
1.6% |
| Pyrexia |
1.6% |
| Urine Output Decreased |
1.6% |
|
| Concomitant |
| Epilepsy |
44.1% |
| Complex Partial Seizures |
10.3% |
| Grand Mal Convulsion |
8.3% |
| Simple Partial Seizures |
8.3% |
| Prophylaxis |
7.6% |
| Product Used For Unknown Indication |
4.1% |
| Convulsion |
3.4% |
| Glioblastoma Multiforme |
2.8% |
| Chronic Hepatitis C |
2.1% |
| Bipolar Ii Disorder |
1.4% |
| Multiple Sclerosis |
1.4% |
| Anaplastic Astrocytoma |
0.7% |
| Antifungal Prophylaxis |
0.7% |
| Antipyresis |
0.7% |
| Delusion |
0.7% |
| Diabetes Mellitus |
0.7% |
| Drug Use For Unknown Indication |
0.7% |
| Dyslipidaemia |
0.7% |
| Haemostasis |
0.7% |
| Hypersensitivity |
0.7% |
|
| Impulsive Behaviour |
11.1% |
| Completed Suicide |
7.4% |
| Lymphocyte Count Decreased |
7.4% |
| Status Epilepticus |
7.4% |
| Weight Increased |
7.4% |
| White Blood Cell Count Decreased |
7.4% |
| Factor Ix Inhibition |
3.7% |
| Interstitial Lung Disease |
3.7% |
| Nausea |
3.7% |
| Neutrophil Count Decreased |
3.7% |
| Pancreatic Enzymes Increased |
3.7% |
| Pneumonia |
3.7% |
| Pneumonia Aspiration |
3.7% |
| Rash |
3.7% |
| Sudden Unexplained Death In Epilepsy |
3.7% |
| Toxic Epidermal Necrolysis |
3.7% |
| Urticaria |
3.7% |
| Vomiting |
3.7% |
| Weight Decreased |
3.7% |
| White Blood Cell Count Increased |
3.7% |
|
